Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

A critical review of the use of carvedilol in ischemic heart disease.

Chen-Scarabelli C, Saravolatz L Jr, Murad Y, Shieh WS, Qureshi W, Di Rezze J, Abrencillo R, Gardin T, Gidwani UK, Saravolatz L, Faggian G, Scarabelli TM.

Am J Cardiovasc Drugs. 2012 Dec 1;12(6):391-401. doi: 10.2165/11636090-000000000-00000. Review.

PMID:
23061698
2.

Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.

Ruffolo RR Jr, Feuerstein GZ.

Cardiovasc Drugs Ther. 1997 May;11 Suppl 1:247-56. Review.

PMID:
9211017
3.

Beta-blockers in heart failure. The 'new wave' of clinical trials.

Krum H.

Drugs. 1999 Aug;58(2):203-10. Review.

PMID:
10473016
4.

Carvedilol: a nonselective beta blocking agent with antioxidant properties.

Book WM.

Congest Heart Fail. 2002 May-Jun;8(3):173-7, 190. Review. Erratum in: Congest Heart Fail 2002 Jul-Aug;8(4):240.

5.

Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction.

Kopecky SL.

Am J Cardiol. 2006 Oct 15;98(8):1115-9. Epub 2006 Aug 31. Review.

PMID:
17027583
6.
7.

Carvedilol in the treatment of chronic heart failure.

Moe G.

Expert Opin Pharmacother. 2001 May;2(5):831-43. Review.

PMID:
11336626
8.

A review of carvedilol arrhythmia data in clinical trials.

Kowey PR.

J Cardiovasc Pharmacol Ther. 2005 Jun;10 Suppl 1:S59-68. Review.

PMID:
15965573
9.

Carvedilol: just another Beta-blocker or a powerful cardioprotector?

Carreira RS, Monteiro P, Gon Alves LM, ProvidĂȘncia LA.

Cardiovasc Hematol Disord Drug Targets. 2006 Dec;6(4):257-66. Review.

PMID:
17378771
10.

Carvedilol--clinical experience in arrhythmias.

Storstein L.

Cardiology. 1993;82 Suppl 3:29-33. Review.

PMID:
8106161
11.

Carvedilol: a review of its use in chronic heart failure.

Keating GM, Jarvis B.

Drugs. 2003;63(16):1697-741. Review.

PMID:
12904089
12.

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.

Feuerstein GZ, Ruffolo RR Jr.

Eur Heart J. 1996 Apr;17 Suppl B:24-9. Review.

13.

Cardiac remodeling in coronary artery disease.

Sharpe N.

Am J Cardiol. 2004 May 6;93(9A):17B-20B. Review.

PMID:
15144932
14.

Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol.

Feuerstein G, Yue TL, Ma X, Ruffolo RR.

Prog Cardiovasc Dis. 1998 Jul-Aug;41(1 Suppl 1):17-24. Review.

PMID:
9715819
15.
16.

Protective effects of carvedilol in the myocardium.

Feuerstein GZ, Bril A, Ruffolo RR Jr.

Am J Cardiol. 1997 Dec 4;80(11A):41L-45L. Review.

PMID:
9412541
17.

Carvedilol versus other beta-blockers in heart failure.

Doggrell SA.

Expert Opin Investig Drugs. 2001 May;10(5):971-80. Review.

PMID:
11322870
18.

Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).

DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH.

Am J Cardiol. 2013 Mar 1;111(5):765-9. doi: 10.1016/j.amjcard.2012.11.031. Epub 2013 Jan 4. Review.

PMID:
23290925
19.

New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients.

Sackner-Bernstein JD.

Rev Cardiovasc Med. 2003;4 Suppl 3:S25-9. Review.

PMID:
14564231
20.

Sympathetic activation and the role of beta-blockers in chronic heart failure.

Krum H.

Aust N Z J Med. 1999 Jun;29(3):418-27. Review.

PMID:
10868514
Items per page

Supplemental Content

Write to the Help Desk